Related Experiment Video

Updated: Jun 20, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer

Annelie Liljegren1, Jonas Bergh, Roser Castany

  • 1Karolinska Institutet and Karolinska University Hospital, SE-171 76, Stockholm, Sweden. annelie.liljegren@karolinska.se

Breast (Edinburgh, Scotland)
|September 12, 2009
PubMed

Insights

Sunitinib malate (SUTENT), a tyrosine kinase inhibitor, showed promise in treating advanced breast cancer. Combining SUTENT with docetaxel chemotherapy yielded meaningful responses in four patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sunitinib malate (SUTENT) is an oral, multitargeted tyrosine kinase inhibitor.
  • It inhibits pathways crucial for tumor growth, including vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).

Observation:

  • Sunitinib has demonstrated clinical activity as a single agent in metastatic breast cancer.
  • This case report details four patients with advanced/metastatic breast cancer.

Findings:

  • Patients experienced clinically meaningful responses when treated with sunitinib in combination with docetaxel.
  • This combination therapy suggests potential for enhanced clinical benefit.

Implications:

  • Combining sunitinib with chemotherapy may improve outcomes for patients with advanced breast cancer.
  • Further research into combination therapies involving sunitinib is warranted.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...